WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

WuXi Biologics: Spin-Off And New Projects In The Limelight (Rating Upgrade) https://seekingalpha.com/article/4618035-wuxi-biologics-spin-off-new-projects-in-limelight-rating-upgrade Summary • I have a favorable opinion of WuXi Biologics' planned spin-off, which could re-rate its valuations in a positive manner and help to accelerate the future growth of the spun-off business. • WXXWY's disclosures at its recent Investor Day regarding new project count have negative read-throughs for its near-term top-line growth prospects. • I upgrade my investment rating for WuXi Biologics to a Hold following a review of its spin-off plans, but WXXWY isn't a Buy as its business outlook is still unfavorable. ...

https://www.fiercepharma.com/pharma/wuxi-bio-telegraphs-spinoff-its-bioconjugate-subsidiary-xdc

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1275457/company-news/HK6

Was ist hier denn passiert?

https://www.wuppertaler-rundschau.de/wirtschaft/wuxi-biologics-erweitert-den-standort-wuppertal_aid-91442439

Ja.. eigentlich wirkt das alles doch nicht so schlecht

Bin weiterhin fasziniert mit welchem Willen diese Aktie am Boden klebt

https://ir.amicusrx.com/node/22701/html ...On April 18, 2023, Amicus Therapeutics, Inc. (“Amicus”) entered into a Supply and Manufacturing Services Agreement (the “WuXi Agreement”) with WuXi Biologics (Hong Kong) Limited, WuXi Biologics Ireland Limited and WuXi Biologics Germany GmbH (collectively, “WuXi”). Pursuant to the terms of the WuXi Agreement, WuXi has agreed to manufacture and supply to Amicus, and Amicus has agreed to purchase from WuXi, both the active pharmaceutical ingredient (“API”) in ATB200 and the finished enzyme replacement drug product, consisting of the API formulated as a finished dosage form according to certain specifications (the “Drug Product”).  ... The WuXi Agreement has an initial term of five years from the effective date of the agreement, followed by successive two-year automatic renewal periods.  ...  

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1261286/company-news/HK6

https://www.prnewswire.com/news-releases/wuxi-biologics-congratulates-amicus-therapeutics-on-european-commission-approval-for-pombiliti-in-patients-with-late-onset-pompe-disease-301783244.html

Also das klingt ja alles vielversprechend. Der Kurs spiegelt die positiven Ergebnisse ja noch nicht besonders wider.

https://www.prnewswire.com/news-releases/wuxi-biologics-reports-remarkable-2022-annual-results-301778513.html WuXi Biologics Reports Remarkable 2022 Annual Results

🎈

https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/with-wuxi-biologics-cayman-incs-hkg2269-price-down-59-this-w/amp

https://seekingalpha.com/article/4580154-after-2022-slowdown-wuxi-biologics-gets-growth-medicine-big-new-order After 2022 Slowdown, WuXi Biologics Gets Growth Medicine From Big New Order Summary • WuXi Biologics revenue growth slowed sharply to 48.4% last year, but it got a jumpstart with its signing of a major new order last month. • The company's major shareholder recently sold 56 million shares, the latest in a steady series of such sales since its listing in 2017. • Investors are likely drawn to the company’s steady growth, though it will need to show it can return to the high-growth fast lane after last year’s modest slowdown. ...